175 related articles for article (PubMed ID: 16981000)
1. Cyclosporine short infusion and C2 monitoring in haematopoietic stem cell transplant recipients.
Hendriks MP; Blijlevens NM; Schattenberg AV; Burger DM; Donnelly JP
Bone Marrow Transplant; 2006 Oct; 38(7):521-5. PubMed ID: 16981000
[TBL] [Abstract][Full Text] [Related]
2. Cyclosporine A (CsA) 2-h concentrations vary between patients without correlation to graft-versus-host disease after allogeneic haematopoietic stem cell transplantation.
Barkholt L; Remberger M; Bodegård H; Ringdén O; Böttiger Y
Bone Marrow Transplant; 2007 Oct; 40(7):683-9. PubMed ID: 17660840
[TBL] [Abstract][Full Text] [Related]
3. Single time point measurement by C2 or C3 is highly predictive in cyclosporine area under the curve estimation immediately after lung transplantation.
Hangler HB; Ruttmann E; Geltner C; Bucher B; Nagiller J; Laufer G; Mueller LC
Clin Transplant; 2008; 22(1):35-40. PubMed ID: 18217903
[TBL] [Abstract][Full Text] [Related]
4. Association between cyclosporine concentrations at 2 hours post-dose and clinical outcomes in de novo lung transplant recipients.
Akhlaghi F; Gonzalez L; Trull AK
J Heart Lung Transplant; 2005 Dec; 24(12):2120-8. PubMed ID: 16364860
[TBL] [Abstract][Full Text] [Related]
5. Limitations of cyclosporine C2 monitoring in pediatric heart transplant recipients.
Hmiel SP; Canter C; Shepherd R; Lassa-Claxton S; Nadler M
Pediatr Transplant; 2007 Aug; 11(5):524-9. PubMed ID: 17631021
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetic monitoring of intravenous cyclosporine A in pediatric stem-cell transplant recipients. The trough level is not enough.
Schrauder A; Saleh S; Sykora KW; Hoy H; Welte K; Boos J; Hempel G; Grigull L
Pediatr Transplant; 2009 Jun; 13(4):444-50. PubMed ID: 18482216
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics of cyclosporine A at a high-peak concentration of twice-daily infusion and oral administration in allogeneic haematopoietic stem cell transplantation.
Inoue Y; Saito T; Ogawa K; Nishio Y; Kosugi S; Suzuki Y; Shibuya Y; Kato M; Takahashi M; Miura I
J Clin Pharm Ther; 2011 Aug; 36(4):518-24. PubMed ID: 21105879
[TBL] [Abstract][Full Text] [Related]
8. Determination of area under the whole blood concentration versus time curve after first intravenous cyclosporine dose in children undergoing hematopoietic stem cell transplant: limited sampling strategies.
Sibbald C; Seto W; Taylor T; Saunders EF; Doyle J; Dupuis LL
Ther Drug Monit; 2008 Aug; 30(4):434-8. PubMed ID: 18641547
[TBL] [Abstract][Full Text] [Related]
9. Advantages of C2 monitoring to avoid acute rejection in pediatric heart transplant recipients.
Schubert S; Abdul-Khaliq H; Lehmkuhl HB; Hübler M; Abd El Rahman MY; Miera O; Ewert P; Weng Y; Wei H; Krüdewagen B; Hetzer R; Berger F
J Heart Lung Transplant; 2006 Jun; 25(6):619-25. PubMed ID: 16730566
[TBL] [Abstract][Full Text] [Related]
10. Study of cyclosporine level at 2 hours after administration in preoperative kidney transplant recipients for prediction of postoperative optimal cyclosporine dose.
Sukhavasharin N; Praditpornsilpa K; Avihingsanon Y; Kuoatawintu P; O-Charoen R; Kansanabuch T; Tungsanga K; Eiam-Ong S
J Med Assoc Thai; 2006 Aug; 89 Suppl 2():S15-20. PubMed ID: 17044449
[TBL] [Abstract][Full Text] [Related]
11. Evolution of the absorption profile of cyclosporine A in renal transplant recipients: a longitudinal study of the de novo and maintenance phases.
Büchler M; Chadban S; Cole E; Midtvedt K; Thervet E; Prestele H; Keown P
Nephrol Dial Transplant; 2006 Jan; 21(1):197-202. PubMed ID: 16204301
[TBL] [Abstract][Full Text] [Related]
12. CsA 2-h concentration correlates best with area under the concentration-time curve after allo-SCT compared with trough CsA.
Kong DC; Shuttleworth P; Bailey M; Grigg A
Bone Marrow Transplant; 2012 Jan; 47(1):54-9. PubMed ID: 21317937
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetic study of the new cyclosporine-A formulation (Neoral) in adult allogeneic bone marrow transplant recipients.
Dotti G; Gaspari F; Caruso R; Perico N; Remuzzi G; Barbui T; Rambaldi A
Haematologica; 2001 Mar; 86(3):311-5. PubMed ID: 11255279
[TBL] [Abstract][Full Text] [Related]
14. C2 monitoring in maintenance renal transplant recipients: is it worthwhile?
Midtvedt K; Fauchald P; Bergan S; Høieggen A; Hallan S; Svarstad E; Bergrem H; Eriksen BO; Pfeffer PF; Dalen I; Leivestad T
Transplantation; 2003 Oct; 76(8):1236-8. PubMed ID: 14578761
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics and pharmacodynamics in renal transplant recipients under treatment with cyclosporine and Myfortic.
Brunet M; Crespo M; Millán O; Serón D; Torregrosa V; Jiménez O; Moreso F; Martorell J; Grinyo JM; Oppenheimer F
Transplant Proc; 2007 Sep; 39(7):2160-2. PubMed ID: 17889124
[TBL] [Abstract][Full Text] [Related]
16. Monitoring C2 level predicts exposure in maintenance lung transplant patients receiving the microemulsion formulation of cyclosporine (Neoral).
Jaksch P; Kocher A; Neuhauser P; Sarahrudi K; Seweryn J; Wisser W; Klepetko W
J Heart Lung Transplant; 2005 Aug; 24(8):1076-80. PubMed ID: 16102443
[TBL] [Abstract][Full Text] [Related]
17. Achieving adequate cyclosporine exposure in liver transplant recipients: a novel strategy for monitoring and dosing using intravenous therapy.
Lück R; Böger J; Kuse E; Klempnauer J; Nashan B
Liver Transpl; 2004 May; 10(5):686-91. PubMed ID: 15108262
[TBL] [Abstract][Full Text] [Related]
18. Abbreviated AUC monitoring of cyclosporine more adequately identified patients at risk for acute rejection during induction of immunosuppressive therapy after kidney transplantation than recommended C2 concentration values.
Troncoso P; Ortiz AM; Jara A; Vilches S
Transplant Proc; 2009; 41(1):127-30. PubMed ID: 19249495
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics of CsA during the switch from continuous intravenous infusion to oral administration after allogeneic hematopoietic stem cell transplantation.
Kimura S; Oshima K; Okuda S; Sato K; Sato M; Terasako K; Nakasone H; Kako S; Yamazaki R; Tanaka Y; Tanihara A; Higuchi T; Nishida J; Kanda Y
Bone Marrow Transplant; 2010 Jun; 45(6):1088-94. PubMed ID: 19898510
[TBL] [Abstract][Full Text] [Related]
20. Three-years experience with Neoral C2 monitoring adjusted to a target range of 500-600 ng/ml in long-term renal transplant recipients receiving dual immunosuppressive therapy.
Carstens J
Scand J Urol Nephrol; 2008; 42(3):286-92. PubMed ID: 18432535
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
